header

Subscribe our Newsletter!

Browse our Calendar!

Mon Tue Wed Thu Fri Sat Sun
1
Date : Thursday, 01 December 2016
2
3
4
5
7
8
9
10
11
12
13
Date : Tuesday, 13 December 2016
14
15
16
17
18
19
20
21
22
23
24
25
27
28
29
30
31

BLUE GROWTH 1024x616

... And what Blue Growth really is? Is the EU going to have an impact? (see: source).

For a couple of years now Brussels is discussing this topic. Come and give a closer look on the latest developments, as discussed by the Institutions and the private sector. Now and in the coming months, this will be one of the key topic followed by EU Events.

EUevents Big Pharma

Can the European Medicines Agency (EMA) be truly independent, if it also is in close contact with the pharmaceutical industry? Last week , experts discussed this (and other related topics) at our event in the European Parliament, which Wemos co-organized with the European Parliament group of SP (GUE/NGL).

During the event on 9 January, the experts discussed EMA’s way of working and its relations with the pharmaceutical industry. Some stressed that conflicts of interest exist in all sectors, and that EMA – in order to operate properly – in fact needs its contacts with the industry. According to Noel Wathion (deputy Executive Director of EMA), the agency has a robust system of checks and balances.

brexit-fuga-da-londra

Photo credits

Brexit has never left the European agenda since its beginning. Now that it is finally shaping up, it remains one of the most controversial topic debated in Brussels. Follow with EU Events the many aspects and implications, as viewed and reviewed by policy-makers and experts.

Page 1 of 15